In the HER2-negative breast cancer cohort treated with Bevacizumab, MMP2, COL5A2, COL6A1, DLK1, and MDK were identified as predictive of treatment response, aligning with their documented roles in angiogenesis and stromal interactions. Here, COL6A1 is linked to breast cancer.